Pharmasset ( VRUS) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole was unchanged today. By the end of trading, Pharmasset fell $4.04 (-3.2%) to $123.75 on heavy volume. Throughout the day, 6.1 million shares of Pharmasset exchanged hands as compared to its average daily volume of 2.2 million shares. The stock ranged in price between $122.53-$125.69 after having opened the day at $125.43 as compared to the previous trading day's close of $127.79. Other company's within the Drugs industry that declined today were: StemCells ( STEM), down 40.7%, Aoxing Pharmaceutical Company ( AXN), down 34.2%, Inhibitex ( INHX), down 19.5%, and K-V Pharmaceutical Company ( KV.B), down 17.7%.

Pharmasset, Inc., a clinical-stage pharmaceutical company, engages in discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset has a market cap of $9.68 billion and is part of the health care sector. Shares are up 487.2% year to date as of the close of trading on Thursday. Currently there are six analysts that rate Pharmasset a buy, one analyst rates it a sell, and nine rate it a hold.

TheStreet Ratings rates Pharmasset as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, weak operating cash flow and deteriorating net income.

On the positive front, Ista Pharmaceuticals ( ISTA), up 71.7%, China Shenghuo Pharmaceutical Holdings ( KUN), up 48.4%, BioTime ( BTX), up 14.2%, and PharmAthene ( PIP), up 12.7%, were all gainers within the drugs industry with Alexion Pharmaceuticals ( ALXN) being today's featured drugs industry winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).
null

If you liked this article you might like

Idenix Pharma's Hep C Drug Safe But Slow (And Ready For Sale)

Hep C Deal-A-Palooza: Bristol-Myers Buys Inhibitex for $2.5 Billion

Inhibitex Shares Whipsawed by Cautious Analyst Comment

5 Big Surprise Stock Winners of 2011

5 Big Surprise Stock Winners of 2011

'Fast Money' Recap: Beaten-Up Financials Eyed